{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:15:31Z","timestamp":1761218131966,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T00:00:00Z","timestamp":1550275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: Recent studies suggest that a vascular endothelial growth factor (VEGF-A) may be involved in the thrombotic process by stimulating the expression of tissue factor in vascular endothelial cells. Tissue factor (TF) can also stimulate the transcription of the gene encoding VEGF-A. The relationship between coagulation and angiogenesis in myeloproliferative neoplasms is not fully understood. The aim of this study was to evaluate the concentration of TF in relation to VEGF-A in the blood of patients with essential thrombocythemia (ET). Patients and methods: The study group consisted of 130, newly diagnosed patients with ET (mean age 61 years). The control group consisted of 35 healthy volunteers (mean age 51 years). Concentrations of VEGF-A, TF, and tissue factor pathway inhibitor (TFPI) were analysed using immunoenzymatic methods. TF and TFPI activities were performed using chromogenic assays. Results: The median concentration of TF Ag was 3-fold higher and the TF activity was more than 15-fold higher in ET patients than in normal individuals. There were no statistically significant differences in the TFPI concentration and activity between groups. VEGF-A was significantly increased in patients with ET (p &lt; 0.000001). Analysis of correlations revealed a positive correlation between VEGF-A and TF Ag as well as a positive correlation between VEGF-A and TFPI activity. Conclusions: The simultaneous increase of TF concentration and activity, VEGF-A in the blood of patients with ET, as well as a positive correlation between the concentration of TF and VEGF-A demonstrates the coexistence of TF-dependent coagulation and activation of angiogenesis.<\/jats:p>","DOI":"10.3390\/medicina55020054","type":"journal-article","created":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T22:11:50Z","timestamp":1550441510000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Activation of TF-Dependent Blood Coagulation Pathway and VEGF-A in Patients with Essential Thrombocythemia"],"prefix":"10.3390","volume":"55","author":[{"given":"Gra\u017cyna","family":"Gadomska","sequence":"first","affiliation":[{"name":"Department of Hematology and Malignant Diseases of Hematopoietic System, Faculty of Medicine, Nicolaus Copernicus University in Toru\u0144, Collegium Medicum in Bydgoszcz, 85-168 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Zio\u0142kowska","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University in Toru\u0144, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Boinska","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University in Toru\u0144, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Filipiak","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University in Toru\u0144, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta","family":"Ro\u015b\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University in Toru\u0144, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0001-5814(12)33004-1","article-title":"Haemostasis disturbances in polycythemia vera and essential thrombocythemia","volume":"43","author":"Szumowska","year":"2012","journal-title":"Acta Haematol. Pol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: Frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Cervantes","year":"2007","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and JAK2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"ref_6","first-page":"1","article-title":"Tissue factor pathway inhibitor [Tfpi]: A natural coagulation inhibitor and potential therapeutic agent\u2014A review","volume":"4","year":"2009","journal-title":"J. Taibah Univ. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/MBC.0000000000000551","article-title":"Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia","volume":"27","author":"Gadomska","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_8","first-page":"340","article-title":"Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia","volume":"126","author":"Stankowska","year":"2016","journal-title":"Pol. Arch. Med. Wewn."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"367284","DOI":"10.4061\/2011\/367284","article-title":"Tissue factor, blood coagulation, and beyond: An overview","volume":"2011","author":"Chu","year":"2011","journal-title":"Int. J. Inflamm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1200\/JCO.2009.22.6324","article-title":"Role of tissue factor in cancer","volume":"27","author":"Kasthuri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ajh.10061","article-title":"Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer","volume":"69","author":"Nakasaki","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-04-2661","article-title":"Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review","volume":"11","author":"Singhal","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.105.567297","article-title":"Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications","volume":"113","author":"Steffel","year":"2006","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9440(10)64511-7","article-title":"Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity","volume":"157","author":"Lundberg","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2040-2384-2-10","article-title":"Clinical trials with anti-angiogenic agents in hematological malignancies","volume":"2","author":"Medinger","year":"2010","journal-title":"J. Angiogenes Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2141.2007.06885.x","article-title":"Bone marrow microvessel density in chronic myeloproliferative disorders: A study of 115 patients with clinicopathological and molecular correlations","volume":"140","author":"Boveri","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<14::AID-AJH3>3.0.CO;2-9","article-title":"Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis","volume":"52","author":"Bucalossi","year":"1996","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","article-title":"Thrombotic disease in the myeloproliferative neoplasms","volume":"2012","author":"Falanga","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ajh.21974","article-title":"Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Marchetti","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: Relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_21","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Reverter","year":"2006","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.20399","article-title":"Treatment of symptomatic patients with essential thrombocythemia: Effectiveness of anagrelide","volume":"80","author":"Cacciola","year":"2005","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajh.10020","article-title":"Soluble angiogenic factor: Implications for chronic myeloproliferative disorders","volume":"69","author":"Musolino","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gadomska, G., Stankowska, K., Boinska, J., \u015alusarz, R., Tylicka, M., Michalska, M., Jachalska, A., and Ro\u015b\u0107, D. (2017). VEGF-A, sVEGFR-1 and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms. Medicina.","DOI":"10.1016\/j.medici.2017.01.004"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.neo.7900184","article-title":"The hemostatic system and angiogenesis in malignancy","volume":"3","author":"Wojtukiewicz","year":"2001","journal-title":"Neoplasia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02981930","article-title":"The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: Tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer","volume":"73","author":"Rickles","year":"2001","journal-title":"Int. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.leu.2404264","article-title":"Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies","volume":"20","author":"Barbarroja","year":"2006","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/bst0300173","article-title":"Mechanism of thrombin-induced angiogenesis","volume":"30","author":"Maragoudakis","year":"2002","journal-title":"Biochem. Soc. Trans."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1242\/jcs.03409","article-title":"Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer","volume":"120","author":"Arora","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2004-822971","article-title":"Role of thrombin in angiogenesis and tumor progression","volume":"30","author":"Tsopanoglou","year":"2004","journal-title":"Semin. Thromb. Hemost."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/2\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:32:38Z","timestamp":1760185958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/2\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,16]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["medicina55020054"],"URL":"https:\/\/doi.org\/10.3390\/medicina55020054","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2019,2,16]]}}}